International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 212-220
| Back | Table of Contents | PDF | Mail to Author | |
Serum PADI4 Levels in Neutropenia and Febrile Neutropenia
Basak UNVER KOLUMAN1, Esin AVCI2, Tuba KOKSOY2, Hande SENOL3, Gulsum AKGUN CAGLIYAN1, Sibel HACIOGLU1
1Pamukkale University Faculty of Medicine, Department of Hematology
2Pamukkale University Faculty of Medicine, Department of Biochemistry
3Pamukkale University Faculty of Medicine, Department of Biostatistics
Keywords: PADI4 protein, Neutropenia, Febrile neutropenia, Hematologic malignancies
Peptidyl arginine deiminase (PADI) enzymes catalyze the conversion of peptidylarginine to peptidylcitrulline and are involved in the extracellular neutrophil trapping (NET) process. PADI4 is one of the most important PADI isoforms since it is the only PADI isotype with a nuclear localization signal and is found in tissues such as granulocytes, monocytes, and CD34(+) bone marrow cells. It contributes to the genesis of certain illnesses, such as autoimmune inflammatory diseases and cancer. In this investigation, we assessed PADI4 levels in patients with hematological malignancies that are neutropenic and compared them to hospitalized patients’ neutropenic fever periods. PADI4 levels were lower in patients with neutropenic hematological malignancies than in the control group (4.44 ± 2.76 ng/ ml (med: 3.98, IQR: 3-4.58) vs. 6.14 ± 6 .39 ng/ml (med: 2.7, IQR: 2.32-9.5); p= 0.049). It was shown that the patients with neutropenic fever had serum PADI4 levels that were statistically substantially lower than those of the control group (4.65 ± 2.54 ng/ml (med: 3.98, IQR: 3.24-5.17) vs. 6.14± 6.39 (med: 2.7, IQR: 2.32-9.5; p= 0.05). There was no statistically significant difference in PADI4 level between the neutropenic group and the neutropenic fever group (p= 0.734). PADI4 might be significant because of its potential to be a target in the management of infectious complications and neutropenic hematological malignancies. We require further research in this area.
Basak UNVER KOLUMAN1, Esin AVCI2, Tuba KOKSOY2, Hande SENOL3, Gulsum AKGUN CAGLIYAN1, Sibel HACIOGLU1
1Pamukkale University Faculty of Medicine, Department of Hematology
2Pamukkale University Faculty of Medicine, Department of Biochemistry
3Pamukkale University Faculty of Medicine, Department of Biostatistics
Keywords: PADI4 protein, Neutropenia, Febrile neutropenia, Hematologic malignancies
Peptidyl arginine deiminase (PADI) enzymes catalyze the conversion of peptidylarginine to peptidylcitrulline and are involved in the extracellular neutrophil trapping (NET) process. PADI4 is one of the most important PADI isoforms since it is the only PADI isotype with a nuclear localization signal and is found in tissues such as granulocytes, monocytes, and CD34(+) bone marrow cells. It contributes to the genesis of certain illnesses, such as autoimmune inflammatory diseases and cancer. In this investigation, we assessed PADI4 levels in patients with hematological malignancies that are neutropenic and compared them to hospitalized patients’ neutropenic fever periods. PADI4 levels were lower in patients with neutropenic hematological malignancies than in the control group (4.44 ± 2.76 ng/ ml (med: 3.98, IQR: 3-4.58) vs. 6.14 ± 6 .39 ng/ml (med: 2.7, IQR: 2.32-9.5); p= 0.049). It was shown that the patients with neutropenic fever had serum PADI4 levels that were statistically substantially lower than those of the control group (4.65 ± 2.54 ng/ml (med: 3.98, IQR: 3.24-5.17) vs. 6.14± 6.39 (med: 2.7, IQR: 2.32-9.5; p= 0.05). There was no statistically significant difference in PADI4 level between the neutropenic group and the neutropenic fever group (p= 0.734). PADI4 might be significant because of its potential to be a target in the management of infectious complications and neutropenic hematological malignancies. We require further research in this area.
| Back | Table of Contents | PDF | Mail to Author | |